Padalino Massimo A, Tessari Chiara, Guariento Alvise, Frigo Anna C, Vida Vladimiro L, Marcolongo Andrea, Zanella Fabio, Harvey Michael J, Thiagarajan Ravi R, Stellin Giovanni
Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Italy.
Department of Business and Administration, University Hospital, Padova, Italy.
Interact Cardiovasc Thorac Surg. 2017 Apr 1;24(4):590-597. doi: 10.1093/icvts/ivw381.
Extracorporeal membrane oxygenation (ECMO) is a lifesaving but expensive therapy in terms of financial, technical and human resources. We report our experience with a 'basic' ECMO support model, consisting of ECMO initiated and managed without the constant presence of a bedside specialist, to assess safety, clinical outcomes and financial impact on our health system.
We did a retrospective single-centre study of paediatric cardiac ECMO between January 2001 and March 2014. Outcomes included postimplant complications and survival at weaning and at discharge. We used activity based costing to compare the costs of current basic ECMO with those of a 'full optional' dedicated ECMO team (hypothesis 1); ECMO with a bedside nurse and perfusionist (hypothesis 2), and ECMO with a bedside perfusionist (hypothesis 3).
Basic cardiac ECMO was required for 121 patients (median age 75 days, median weight 4.4 kg). A total of 107 patients (88%) had congenital heart disease; 37 had univentricular physiology. The median duration of ECMO was 7 days (interquartile range [IQR], 4-15 days). Overall survival at weaning and at 30 days in the neonatal and paediatric age groups was 58.6% and 30.6%, respectively; these results were not significantly different from Extracorporeal Life Support Organization data. Cost analysis revealed a saving of €30 366, €22 144 and €13 837 for each patient on basic ECMO for hypotheses 1, 2 and 3, respectively.
Despite reduced human, technical and economical resources, a basic ECMO model without a bedside specialist was associated with satisfactory survival and lower costs.
体外膜肺氧合(ECMO)是一种挽救生命但在资金、技术和人力资源方面成本高昂的治疗方法。我们报告了我们使用“基础”ECMO支持模式的经验,该模式在启动和管理ECMO时无需床边专科医生持续在场,以评估其安全性、临床结果以及对我们医疗系统的财务影响。
我们对2001年1月至2014年3月期间接受儿科心脏ECMO治疗的患者进行了一项回顾性单中心研究。结果包括植入后并发症以及撤机时和出院时的生存率。我们采用作业成本法比较了当前基础ECMO与“全选”专用ECMO团队(假设1)、配备床边护士和灌注师的ECMO(假设2)以及配备床边灌注师的ECMO(假设3)的成本。
121例患者(中位年龄75天,中位体重4.4千克)需要进行基础心脏ECMO治疗。共有107例患者(88%)患有先天性心脏病;37例有单心室生理结构。ECMO的中位持续时间为7天(四分位间距[IQR],4 - 15天)。新生儿和儿科年龄组撤机时和30天时的总体生存率分别为58.6%和30.6%;这些结果与体外生命支持组织的数据无显著差异。成本分析显示,对于假设1、2和3,接受基础ECMO治疗的每位患者分别节省了30366欧元、22144欧元和13837欧元。
尽管人力、技术和经济资源减少,但无需床边专科医生的基础ECMO模式仍具有令人满意的生存率且成本较低。